Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study

CONCLUSION: The NFOSI-18 DRS-P scale is responsive to clinical change. It has potential as an indicator of changing health status with ovarian cancer disease progression, distinct from treatment side effects.PMID:34548162 | DOI:10.1016/j.ygyno.2021.08.028

Source: Ann Oncol - September 22, 2021 Category: Cancer & Oncology Authors: Lari Wenzel Helen Q Huang David Cella Chelsea O McKinney Michael A Zevon Jason A LaChance Joan L Walker Ritu Salani Susan C Modesitt Robert T Morris William H Bradley Matthew P Boente Vivian E von Gruenigen Source Type: research